Kidswell Bio Corp. (4584)

Overview

Kidswell Bio Corporation is a biopharmaceutical company based in Tokyo, Japan, specializing in the development of medications for rare and difficult-to-treat diseases. Since its establishment in 2001, originally known as Gene Techno Science Co., Ltd., the company has focused on addressing unmet medical needs in various therapeutic areas, including ophthalmic diseases, oncology, immunological disorders, and more. In July 2021, it underwent a rebranding to Kidswell Bio Corporation, reflecting possibly a refined focus or expansion in its research and development efforts. Operated mainly in Japan, the company aims to contribute significantly to the advancement of medical science and the improvement of patient outcomes through its innovative drug development pipeline.

Products and Services

The company's robust pipeline features a diverse range of treatments in development for several medical conditions:

• GND-004 - This product is under development for both ophthalmic diseases and oncology. While specific details of its mechanism of action or therapeutic approach are not disclosed, its dual focus suggests a versatile platform technology or compound with broad applicability in treating eye diseases and cancers.
• GND-007 - Targeting immunological diseases, this candidate represents Kidswell Bio Corporation's commitment to addressing conditions driven by immune system dysfunction, potentially offering new hope for patients with limited treatment options.
• GBS Series (Oncology) - The GBS series, including GBS-001, GBS-004, and GBS-010, are focused on oncology. These products showcase the company's efforts in developing targeted therapies for cancer, an area with a perpetual need for more effective and less toxic treatments.
• GBS-005 - This candidate is tailored towards the treatment of immunological diseases, similar to GND-007, highlighting the company's recurrent focus on immune-mediated conditions.
• GBS Series (Other Diseases) - Within this series are GBS-007 and GBS-012 for ophthalmic diseases, GBS-008 for infectious diseases, and GBS-011 for renal diseases. Each of these developments signifies targeted research efforts aimed at providing novel solutions for these specific health challenges.
• GCT Series (Rare Diseases) - The GCT series, including GCT-101 for alveolar cleft and GCT-102 for congenital isolated hypoganglionosis, underscores Kidswell Bio Corporation’s commitment to tackling rare and pediatric diseases, areas often overlooked in drug development.
• Other Pipeline Products - The company also has several other products in development for a range of conditions including ophthalmologic diseases, cerebral palsy, peripheral nerve palsy, fracture, and spinal cord injury. These initiatives reflect Kidswell Bio Corporation's broad approach to improving healthcare outcomes across a wide spectrum of ailments.